AEterna Zentaris Inc. (NASDAQ: AEZS) this week disclosed the positive headline data from its Phase 2 trial with Ozarelix (D-63153) for patients suffering from hormone-dependent inoperable prostate cancer.
The study was able to define a tolerable dosage regimen of ozarelix that would ensure continuous suppression of testosterone at castration level (< 0.5 ng/ml) for a three-month test period.
"We are very excited with these results which confirm the mechanism of action of our LHRH antagonist approach and the potential effectiveness of ozarelix to achieve sustained suppression of sexual hormones at castration levels and, consequently, could allow for the treatment of hormone-dependent cancers.
Now that we have a suitable dosage regimen of ozarelix for the potential treatment of prostate cancer, we are pleased to further advance the clinical development of ozarelix in this indication with a Phase 2b program," commented Dr. Jurgen Engel, Executive Vice President, Global R&D and Chief Operating Officer at AEterna Zentaris.
The trial was conducted in Europe in collaboration with AEterna Zentaris' partner Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
Read more at AEterna Zentaris Inc.
.jpg)
Comment Preview